Comparison of in vivo efficacy of BCX-1777 and cyclosporin in xenogeneic graft-vs.-host disease: the role of dGTP in antiproliferative action of BCX-1777
- 30 June 2002
- journal article
- research article
- Published by Elsevier BV in International Immunopharmacology
- Vol. 2 (7), 913-923
- https://doi.org/10.1016/s1567-5769(02)00034-6
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)—a novel potent and orally active immunosuppressive agentInternational Immunopharmacology, 2001
- Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytesProceedings of the National Academy of Sciences, 2001
- Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cellsImmunopharmacology, 1998
- One-Third-the-Sites Transition-State Inhibitors for Purine Nucleoside PhosphorylaseBiochemistry, 1998
- In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTPImmunopharmacology, 1996
- A HUMAN MODEL OF XENOGENEIC GRAFT-VERSUS-HOST DISEASE IN SCID MICE ENGRAFTED WITH HUMAN PERIPHERAL BLOOD LYMPHOCYTESTransplantation, 1995
- Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primersAnalytical Biochemistry, 1989
- Abnormal Purine Metabolism and Purine Overproduction in a Patient Deficient in Purine Nucleoside PhosphorylaseNew England Journal of Medicine, 1976
- An abnormal form of purine nucleoside phosphorylase in a family with a child with severe defective T-cell-and normal B-cell immunityClinica Chimica Acta; International Journal of Clinical Chemistry, 1976
- NUCLEOSIDE-PHOSPHORYLASE DEFICIENCY IN A CHILD WITH SEVERELY DEFECTIVE T-CELL IMMUNITY AND NORMAL B-CELL IMMUNITYThe Lancet, 1975